UroGen Pharma (URGN) Finished Goods (2020 - 2021)

UroGen Pharma's (URGN) quarterly Finished Goods came in at $888000.0 in Q1 2021, down 2.74% on a QoQ basis from $913000.0 in Q4 2020.

UroGen Pharma (URGN) Finished Goods (2020 - 2021) Analysis & Trends

UroGen Pharma (URGN) has 2 years of Finished Goods data on file, last reported at $888000.0 in Q1 2021.

Quarterly Finished Goods changed N/A year-over-year to $888000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $888000.0 (changed N/A YoY) and the FY2020 annual result came in at $913000.0, changed N/A from the prior year.
Finished Goods eased to $888000.0 in Q1 2021, from $913000.0 in the prior quarter.
In the past five years, Finished Goods ranged from a high of $913000.0 in Q4 2020 to a low of $232000.0 in Q2 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	UroGen Pharma	2.36 Bn	2.25 Bn	65.88 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2021	888,000.00
Dec 31, 2020	913,000.00
Sep 30, 2020	419,000.00
Jun 30, 2020	232,000.00